Login / Signup

Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA.

Nicolas A MargotNina PennetzdorferVidula NaikMartin RheeChristian Callebaut
Published in: Antiviral therapy (2023)
sequence from EI-resistant isolates did not affect LEN susceptibility. The lack of cross-resistance to LEN across ARV-resistant isolates supports the use of LEN in PWH regardless of their treatment history. During the second half-year period of the CAPELLA Study, development of LEN resistance was rare and was overall associated with functional LEN monotherapy due to either nonadherence or resistance-driven non-susceptibility to OBR.
Keyphrases
  • randomized controlled trial
  • study protocol
  • smoking cessation
  • replacement therapy
  • double blind